NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-29 20:54இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
CARE Ratings Q2 FY27 Consolidated PAT Up 26% YoY to ₹72.37 Cr; ₹10 Interim Dividend
CARE Ratings reported strong Q2 FY27 results with consolidated operating income rising 20% YoY to ₹164.13 crore and PAT growing 26% YoY to ₹72.37 crore. Operating performance showed margin expansion, with consolidated EBITDA margin reaching 52% (EBITDA of ₹84.61 crore, up 23% YoY) and PAT margin at 40%. The core ratings segment grew 21% YoY to ₹148.51 crore, while the non-ratings business increased 15% YoY to ₹15.62 crore. The Board also declared an interim dividend of ₹10 per share for the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுCARE Ratings released its Q2 and H1 FY27 financial performance along with the announcement of a ₹10 per share interim dividend.
ஏன் இது முக்கியம்The results demonstrate resilient operating margins above 50% and double-digit top-line expansion, supported by a rebound in debt issuance activity and non-rating diversification.
📅 குறுகிய காலம்Positive reaction expected due to solid 26% PAT growth, margin expansion to 52%, and the ₹10 interim dividend payout.
📈 நீண்ட காலம்Continued expansion into ESG, consulting, analytics, and GIFT City operations enhances non-rating revenue streams and broadens the company's competitive moat.
⚠ அபாய எச்சரிக்கைகள்
Sensitivity to debt market volumes and macroeconomic interest rate cycles
Geopolitical or inflation-driven slowdowns in corporate capex
👀 கவனிக்க வேண்டியவை
Track subsequent growth in corporate bond and commercial paper issuances, alongside execution traction in international and ESG verticals.
CARE Ratings Declares ₹10 Interim Dividend; Sets Record Date as Nov 6, 2026
CARE Ratings has announced an interim dividend of ₹10 per equity share (face value ₹10) for FY 2026-27. The company has fixed November 6, 2026, as the record date to determine eligible shareholders. Concurrently, the Board approved Q2 FY27 results and appointed Mr. Jatindar Pal Singh Bajaj as an Additional Non-Executive Director. The filing also notes definitive agreements signed on October 19, 2026, to divest a 9.90% stake each in subsidiary CareEdge Global IFSC Limited to SBI and NSE IFSC.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Board declared a ₹10 per share interim dividend with a record date of November 6, 2026, and inducted a new Non-Executive Director.
ஏன் இது முக்கியம்Demonstrates consistent cash return to shareholders backed by healthy debt-free operations (TTM PAT of ₹180 Cr, cash and bank balances of ₹73.7 Cr as of Sep 30, 2026).
Interim Dividend per share: Rs. 10ரெக்கார்ட் தேதி: 06-நவ.-2026CareEdge Global IFSC Stake to SBI & NSE IFSC: 9.90% eachRetained stake in CareEdge Global IFSC: 80.20%
📅 குறுகிய காலம்Shares will adjust for the ₹10 dividend around the ex-dividend date; eligible shareholders on the record date of November 6, 2026, will receive payouts per statutory timelines.
📈 நீண்ட காலம்Limited impact from routine dividend distribution; strategic onboarding of SBI and NSE IFSC in the IFSC subsidiary supports long-term international expansion.
👀 கவனிக்க வேண்டியவை
Track the ex-dividend date preceding November 6, 2026, and monitor completion of stake sale actions in subsidiary CareEdge Global IFSC Limited.
CARE Ratings Signs SPAs to Sell 9.90% Each in GIFT City Arm to SBI and NSE IFSC
CARE Ratings Limited has executed Share Purchase Agreements and a Shareholders' Agreement to sell a 9.90% equity stake each in its wholly owned subsidiary, CareEdge Global IFSC Limited (CGIL), to State Bank of India (SBI) and NSE IFSC Limited. Post-transaction, CARE Ratings will retain an 80.20% controlling stake, and CGIL will cease to be a wholly owned subsidiary. The closing actions for the stake sale are expected to be completed within two months, pending CGIL Board approval. Financial deal consideration was not disclosed in the filing.
உச்சம் நம்பிக்கை
என்ன மாறியதுCARE Ratings signed definitive share purchase agreements to divest an aggregate 19.80% stake in CareEdge Global IFSC Limited to strategic institutional partners (SBI and NSE IFSC).
ஏன் இது முக்கியம்Onboarding marquee domestic institutions like SBI and NSE's international exchange brings strategic credibility and ecosystem distribution to CARE's global rating operations at GIFT City, while retaining over 80% control.
Stake sold to SBI: 9.90%Stake sold to NSE IFSC: 9.90%Retained stake in CGIL: 80.20%Transaction timeline: within two monthsDeal consideration: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Neutral to mildly positive; final cash realization or accounting impact will depend on the valuation details once disclosed upon closing.
📈 நீண்ட காலம்Strategically beneficial as equity participation from India's largest lender (SBI) and exchange (NSE IFSC) strengthens CGIL's competitive positioning in international credit ratings at GIFT City.
⚠ அபாய எச்சரிக்கைகள்
Closing actions subject to conditions precedent and CGIL board approval
Financial valuation/consideration not disclosed in the filing
👀 கவனிக்க வேண்டியவை
Track the formal completion of closing actions over the next two months and monitor Q3 FY27 disclosures for any recorded stake sale consideration and exceptional gains.
18.9% Revenue Growth in Q1 FY27; Consolidated PAT Increases 24.6% YoY
CARE Ratings reported a consolidated operating income of ₹111.68 Cr for Q1 FY27, marking an 18.9% YoY increase. Consolidated PAT grew by 24.6% to ₹32.99 Cr, reflecting improved operational efficiency with an EBITDA margin of 31.0%. Despite a 29.3% decline in overall corporate bond issuances in the economy, the company's core ratings business grew 19.1% YoY, supported by strong bank credit growth of 18.6%. The non-ratings segment, including analytics and ESG, contributed ₹12.97 Cr to the top line.
உச்சம் நம்பிக்கை
என்ன மாறியதுCARE Ratings has delivered strong double-digit growth in both revenue and profit for the first quarter of FY27 compared to the same period last year.
ஏன் இது முக்கியம்The results demonstrate the company's ability to grow its ratings business through bank credit demand even when the corporate bond market is muted, while successfully diversifying into ESG and global sovereign ratings.
Consolidated Operating Income (Q1): ₹111.68 கோடிConsolidated PAT (Q1): ₹32.99 கோடிYoY Revenue Growth: 18.9%YoY PAT Growth: 24.6%Consolidated EBITDA Margin: 31.0%Q1 வருவாய் vs TTM வருவாய்: 23.6%
📅 குறுகிய காலம்The stock may see positive sentiment due to the strong bottom-line growth and resilient margins despite macroeconomic headwinds in the bond market.
📈 நீண்ட காலம்The company's expansion into GIFT City and its leadership in the emerging ESG ratings market provide structural growth drivers beyond traditional credit ratings.
⚠ அபாய எச்சரிக்கைகள்
Cyclicality of corporate bond issuances
Potential impact of El Niño on domestic economic growth
High dependence on regulatory mandates
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of margins as the company scales its non-rating businesses and track the recovery of the corporate bond market, which remains a high-margin segment.
16.5% YoY Revenue Growth in Q1 FY27; Standalone PAT at ₹33.88 Cr
CARE Ratings reported a steady Q1 FY27 with standalone revenue from operations growing 16.5% YoY to ₹88.15 Cr. Standalone Net Profit increased by 16.3% YoY to ₹33.88 Cr, despite a significant 42.9% rise in other expenses. The company's international subsidiaries contributed ₹8.61 Cr to the consolidated revenue. EPS for the quarter improved to ₹11.27 from ₹9.72 in the previous year's corresponding quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe filing represents the release of unaudited financial results for the first quarter of the 2026-27 fiscal year.
ஏன் இது முக்கியம்The results demonstrate resilient growth in a seasonally slower quarter, maintaining double-digit top-line and bottom-line expansion despite broader market headwinds in corporate bond issuances.
Standalone Revenue (Q1 FY27): ₹88.15 கோடிStandalone PAT (Q1 FY27): ₹33.88 கோடிYoY Revenue Growth: 16.5%Q1 வருவாய் vs TTM வருவாய்: ~18.6%Subsidiary Revenue Contribution: ₹8.61 கோடி
📅 குறுகிய காலம்The stock may see neutral to positive sentiment as the company maintained its growth momentum and margins in a challenging credit environment.
📈 நீண்ட காலம்Structural growth depends on the successful scaling of non-rating subsidiaries and the recovery of the private capex cycle leading to higher bond issuances.
⚠ அபாய எச்சரிக்கைகள்
Rising operating costs (Other expenses up 42.9% YoY)
Sensitivity to corporate bond market volumes
Dependence on regulatory mandates for credit ratings
👀 கவனிக்க வேண்டியவை
Investors should monitor the growth trajectory of non-rating segments like Analytics and ESG, and track corporate bond issuance volumes which typically influence the core rating business.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
CARE Ratings Approves Rs 14 Final Dividend; Total FY26 Payout Reaches Rs 22 Per Share
CARE Ratings held its 33rd Annual General Meeting on July 03, 2026, where shareholders approved all proposed resolutions with near-unanimous support (over 99.99%). A final dividend of Rs 14 per share was declared, which, combined with the Rs 8 interim dividend, brings the total payout for FY26 to Rs 22 per share. Key administrative approvals included the re-appointment of Mr. Mehul Pandya as Director and M/s. B S R & Co. LLP as Statutory Auditors. The company maintains a strong financial profile with a TTM PAT of Rs 173 Cr and an operating margin of 41.6%.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders have formally ratified the FY26 financial results, the final dividend distribution, and the continuation of key leadership and auditing partners.
ஏன் இது முக்கியம்The high approval ratings (99.99%+) indicate strong shareholder confidence in the current management and the 'Quality Led Growth' strategy, while the dividend provides a tangible yield to investors.
Final Dividend: Rs 14 per shareTotal FY26 Dividend: Rs 22 per shareDividend Yield (Approx): 1.32%TTM வருவாய்: Rs 473 கோடிOperating Profit Margin: 41.6%
📅 குறுகிய காலம்The stock may see neutral to positive sentiment as the final dividend is confirmed, providing clarity on the total yield for the previous fiscal year.
📈 நீண்ட காலம்Limited structural impact as this was a routine AGM; however, the re-appointment of leadership ensures continuity in the company's expansion into GIFT City and global markets.
👀 கவனிக்க வேண்டியவை
Investors should note the final dividend payout and monitor the company's diversification into non-rating segments to offset volatility in corporate bond issuances.
CARE Ratings Appoints 16-Year Veteran Sanjay Agarwal as Chief Risk Officer
CARE Ratings has announced the appointment of Mr. Sanjay Agarwal as Chief Risk Officer (CRO), effective August 1, 2026. Mr. Agarwal is an internal promotion, having served the company for 16 years and currently holding the position of Senior Director. He brings over 30 years of experience in financial services, specializing in risk management and credit analysis. This leadership transition occurs as the company maintains a high operating profit margin of 41.6% and navigates a challenging environment where corporate bond issuances declined by 37% in Q2 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுMr. Sanjay Agarwal, a long-term internal leader, has been designated to take over the Chief Risk Officer role starting August 2026.
ஏன் இது முக்கியம்For a credit rating agency, the CRO is vital for maintaining the analytical integrity and regulatory compliance that sustain its competitive moat and 'Quality Led Growth' strategy.
📅 குறுகிய காலம்The announcement is unlikely to impact the stock price in the short term as the effective date is over a year away and involves an internal promotion.
📈 நீண்ட காலம்The appointment suggests a focus on continuity and internal expertise, which is crucial for maintaining the company's reputation in the highly regulated credit rating industry.
👀 கவனிக்க வேண்டியவை
Monitor for any updates to credit rating methodologies or risk frameworks following the transition in August 2026, particularly as the company expands into ESG and analytics.
CARE Ratings FY26 PAT up 24% to ₹173.7 Cr; AGM Scheduled for July 3, 2026
CARE Ratings Limited has announced its 33rd Annual General Meeting for July 3, 2026, following a strong financial performance in FY 2025-26. The company reported an 18% growth in revenue to ₹473.07 crore and a 24% increase in PAT to ₹173.70 crore. Profitability remains robust with an EBITDA margin of 42% and a PAT margin of 33%. Additionally, the company has fixed June 26, 2026, as the record date for dividend payments.
முக்கிய அம்சங்கள்
Revenue from operations increased 18% YoY to ₹473.07 crore for FY 2025-26.Profit After Tax (PAT) grew by 24% to ₹173.70 crore with an EPS of ₹57.06.Maintains a dominant 58% market share in the ESG ratings (Category 1, Issuer-pays) segment.CareEdge Global expanded sovereign rating coverage to 45 countries, representing 85% of global GDP.Dividend record date and e-voting cut-off set for June 26, 2026.
👀 கவனிக்க வேண்டியவை
Investors should ensure they hold shares by the June 26 record date to qualify for the dividend. The strong margin profile and successful global expansion into sovereign ratings suggest a positive long-term outlook for the stock.
Madras High Court Vacates Asset Alienation Injunction Against CARE Ratings
The Madras High Court has vacated an injunction order dated February 1, 2023, which had previously restrained CARE Ratings from alienating its assets. The vacation of this order on June 3, 2026, follows the company's compliance with court requirements to provide adequate security. This development restores the company's full control over its asset base, although the security was provided without prejudice to the company's ongoing legal appeals.
முக்கிய அம்சங்கள்
Madras High Court vacated the injunction restraining asset alienation on June 3, 2026.The original injunction had been in place since February 1, 2023, pending provision of security.CARE Ratings complied with the security requirements to facilitate the lifting of the restriction.The company received the formal court order on June 4, 2026.Compliance was performed without prejudice to the company's rights in its ongoing appeals.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that removes a significant legal restriction on the company's balance sheet flexibility. Continue to monitor the final outcome of the underlying legal appeals.
CARE Ratings Reports Strong FY26 Performance with 24% PAT Growth and Rs. 14 Final Dividend
CARE Ratings delivered a robust performance for FY26, with consolidated revenue growing 18% YoY to Rs. 473.07 crore and PAT increasing 24% YoY to Rs. 173.69 crore. The company maintained strong profitability, with consolidated EBITDA margins expanding to 42% for the full year. A final dividend of Rs. 14 per share has been recommended, bringing the total dividend for FY26 to Rs. 22 per share. Growth was well-distributed, with the core ratings segment growing 17% and the non-ratings segment increasing by 19%.
முக்கிய அம்சங்கள்
Consolidated PAT for FY26 rose 24% YoY to Rs. 173.69 crore, marking an all-time high.Consolidated Revenue from Operations increased 18% YoY to Rs. 473.07 crore in FY26.Recommended a final dividend of Rs. 14 per share, resulting in a total annual dividend of Rs. 22.Consolidated EBITDA grew by 27% YoY to Rs. 197.39 crore with a margin of 42%.Non-ratings segment revenue grew by 19% YoY to Rs. 50.01 crore, contributing 11% to total revenue.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and the company's successful diversification into non-rating segments. The high dividend yield and strong cash flow generation make it an attractive pick for long-term portfolios.
CARE Ratings Recommends ₹14 Final Dividend and Re-appoints Statutory Auditors
CARE Ratings has recommended a final dividend of ₹14 per equity share for the financial year 2026, with the record date set for June 26, 2026. The company also approved the re-appointment of B S R & Co. LLP as statutory auditors for a five-year term until 2031. Additionally, 55,000 stock options were granted to employees at an exercise price of ₹1,590 per share. The company reported a delay in the partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC due to ongoing legal documentation.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹14 per equity share (Face Value ₹10) for FY26.Re-appointed B S R & Co. LLP as Statutory Auditors for a 5-year term (2026-2031).Granted 55,000 ESOPs under the 2020 scheme at an exercise price of ₹1,590.Partial stake sale of CareEdge Global IFSC to SBI and NSE IFSC is still under negotiation due to documentation delays.
👀 கவனிக்க வேண்டியவை
Investors should ensure they hold shares by the June 26 record date to qualify for the ₹14 dividend. Monitor the eventual closure of the subsidiary stake sale to SBI and NSE IFSC as a potential catalyst for the stock.
CARE Ratings Declares ₹14 Dividend and Grants 55,000 ESOPs at ₹1,590 Exercise Price
CARE Ratings has recommended a final dividend of ₹14 per share for FY26, with the record date set for June 26, 2026. The company also approved the grant of 55,000 stock options to employees at an exercise price of ₹1,590 per share, vesting over three years. Additionally, the board provided an update on the delayed partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC, confirming that negotiations are still active. B S R & Co. LLP has been re-appointed as the statutory auditor for a five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹14 per equity share (Face Value ₹10) for FY26.Granted 55,000 stock options under the 2020 ESOP scheme at an exercise price of ₹1,590.Set June 26, 2026, as the record date for dividend eligibility.Re-appointed B S R & Co. LLP as Statutory Auditors for a five-year term until 2031.Confirmed ongoing negotiations for the stake sale in CareEdge Global IFSC Limited to SBI and NSE IFSC.
👀 கவனிக்க வேண்டியவை
Investors should note the ₹14 dividend and the June 26 record date for eligibility. Monitor the eventual closure of the subsidiary stake sale to SBI and NSE as a potential valuation catalyst.
CARE Ratings & NSE Commercially Launch PaRRVA for Investment Performance Verification
CARE Ratings, in collaboration with the National Stock Exchange (NSE), has commercially launched PaRRVA, a SEBI-conceptualized framework for verifying investment performance. The platform provides independent validation of risk-return metrics for Investment Advisors, Research Analysts, and Trading Members using authenticated market data. By computing nearly 50 different risk and return matrices, PaRRVA aims to eliminate selective performance reporting and enhance transparency in the financial advisory ecosystem. This initiative represents a significant expansion of CARE Ratings' service portfolio into the regulatory compliance and financial analytics space.
முக்கிய அம்சங்கள்
Commercial launch of PaRRVA (Past Risk and Return Verification Agency) following a pilot project initiated in December 2025.Platform computes nearly 50 different risk and return metrics using transaction data directly from stock exchanges and clearing corporations.Features T+1 portfolio validation and end-of-day checks for intraday strategies to ensure high data accuracy and speed.NSE acts as the PaRRVA Data Centre (PDC), providing the necessary infrastructure for authenticated market data.The framework is designed to prevent selective returns presentation and client-specific claims by financial intermediaries.
👀 கவனிக்க வேண்டியவை
Investors should monitor the adoption rate of PaRRVA among financial intermediaries as it establishes a new, high-credibility revenue stream for CARE Ratings. This move strengthens the company's competitive moat in the analytical and regulatory services sector beyond traditional credit ratings.
CARE Ratings to Launch PaRRVA Services from May 4, 2026, Following SEBI Authorization
CARE Ratings Limited has received final authorization from SEBI to commence operations as a Past Risk and Return Verification Agency (PaRRVA) starting May 4, 2026. This follows the successful completion of a pilot phase and initial recognition granted in December 2025. The new service line, established under SEBI's April 2025 framework, allows the company to verify historical performance data for market participants. This development represents a strategic expansion of CARE's service portfolio into regulated verification services.
முக்கிய அம்சங்கள்
Authorized by SEBI to begin PaRRVA services effective from May 4, 2026Authorization follows the successful completion of a pilot-phase mandated by SEBIInitial recognition as a verification agency was previously received on December 5, 2025Service governed under the regulatory framework of SEBI Circular dated April 4, 2025
👀 கவனிக்க வேண்டியவை
Investors should monitor the contribution of this new service line to the company's non-rating revenue in future quarterly results. The expansion into verification services provides a diversified revenue stream and strengthens the company's regulatory standing.
CARE Ratings to Form 50:50 JV 'Operus Limited' for GCC Services with Rs 22.5 Cr Investment
CARE Ratings has approved the incorporation of a joint venture named 'Operus Limited' in partnership with Vestian Global Work Place Services. The JV will focus on Global Capability Centre (GCC) enablement services, assisting global enterprises in designing and operating GCCs in India. CARE Ratings will invest approximately Rs 22.5 crores for a 50% equity stake in the new entity. The incorporation is expected to be completed by June 30, 2026, subject to receiving a No-Objection Certificate from SEBI.
முக்கிய அம்சங்கள்
Formation of a 50:50 Joint Venture with Vestian Global Work Place Services Private Limited.Initial equity capital contribution of Rs 22.5 crores by CARE Ratings at face value.Target entity 'Operus Limited' will provide end-to-end GCC solutions including strategy, talent, and workspace setup.The incorporation process is tentatively scheduled for completion by June 30, 2026.The venture marks a strategic diversification into the high-growth Global Capability Centre enablement sector.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive diversification move that leverages CARE's brand into the consulting and managed services space. Monitor the progress of SEBI approvals and the subsequent scale-up of the GCC enablement business.
CARE Ratings Subsidiary Receives ESG Rating License from IFSCA
CARE Ratings' wholly-owned subsidiary, CareEdge Global IFSC Limited, has successfully obtained a license from the International Financial Services Centres Authority (IFSCA) on March 11, 2026. This license permits the subsidiary to operate as an ESG Rating and Data Product Provider within the International Financial Services Centre. This strategic move allows the company to enter the rapidly growing global market for Environmental, Social, and Governance (ESG) assessments. The expansion diversifies the company's revenue streams beyond traditional credit rating services.
முக்கிய அம்சங்கள்
Wholly-owned subsidiary CareEdge Global IFSC Limited received the IFSCA license on March 11, 2026.Authorized to function as an ESG Rating and Data Product Provider in the IFSC.Positions CARE Ratings to capture demand in the specialized global ESG services market.The license represents a regulatory milestone for the company's international service offerings.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive long-term growth driver that diversifies the company's portfolio. Monitor the scale of operations and revenue contribution from this new ESG vertical in future earnings reports.
CARE Ratings Reports Strong Q3 FY26 Performance with 24% YoY Growth in Consolidated PAT
CARE Ratings Limited reported a robust performance for 9M FY26, with consolidated revenue from operations growing 17% YoY to Rs. 342.40 crore. Profitability saw a significant jump as consolidated PAT rose 24% YoY to Rs. 120.25 crore, driven by operational efficiencies and a 46% standalone EBITDA margin. While the ratings segment remains the core contributor at 89% of revenue, the non-ratings segment showed faster growth at 21% YoY. Despite a 11% decline in corporate bond issuances during Q3, the company benefited from a 14.5% increase in bank credit offtake.
முக்கிய அம்சங்கள்
Consolidated PAT for 9M FY26 grew by 24% YoY to Rs. 120.25 crore with a 32% margin.Consolidated revenue from operations for 9M FY26 increased 17% YoY to Rs. 342.40 crore.Standalone EBITDA margin stood at a healthy 46% for 9M FY26, up from 44% in the previous year.Non-ratings segment revenue grew by 21% YoY to Rs. 36.71 crore, contributing 11% to total revenue.Bank credit offtake accelerated to 14.5% growth as of December 2025, supporting rating volumes.
👀 கவனிக்க வேண்டியவை
Investors should view the strong margin expansion and growth in non-rating segments as positive indicators of business diversification and efficiency. The stock remains a play on the Indian credit cycle and private capex revival, though moderation in bond issuances is a factor to watch.
CARE Ratings Q3 Net Profit Jumps 29% YoY to ₹35.9 Crore; Revenue Up 16%
CARE Ratings reported a strong year-on-year performance for the quarter ended December 31, 2025, with consolidated net profit rising 29.1% to ₹35.9 crore. Revenue from operations grew by 16.3% YoY to ₹112.1 crore, reflecting steady demand in the credit rating and analytics business. While sequential performance showed a decline from the September quarter, the nine-month (9M FY26) net profit remains robust at ₹118.3 crore, a 25% increase over the previous year. The company continues to manage its cost base effectively despite a rise in employee benefit expenses.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations increased 16.3% YoY to ₹112.12 crore in Q3 FY26.Net Profit attributable to owners grew 29.1% YoY to ₹35.90 crore from ₹27.80 crore.9M FY26 Net Profit reached ₹118.34 crore, up 25% compared to ₹94.63 crore in 9M FY25.Total expenses for the quarter rose to ₹76.12 crore, with employee costs accounting for ₹55.13 crore.Other income remained a significant contributor at ₹12.99 crore for the quarter.
👀 கவனிக்க வேண்டியவை
Investors should view the strong year-on-year growth as a positive indicator of the company's market position. The stock remains a key beneficiary of the expanding Indian corporate bond market and credit growth.
CARE Ratings gets SEBI nod as Past Risk and Return Verification Agency (PaRRVA)
CARE Ratings Limited has received final recognition from SEBI to act as a Past Risk and Return Verification Agency (PaRRVA) under SEBI Circular dated April 4, 2025. The National Stock Exchange of India Limited (NSE) will serve as the PaRRVA Data Centre (PDC). CARE Ratings, in collaboration with NSE, will verify the risk–return metrics of Investment Advisers, Research Analysts, and Algorithmic Trading Providers. This recognition is valid until revoked or suspended by SEBI.
முக்கிய அம்சங்கள்
CARE Ratings received final recognition from SEBI as PaRRVA on December 5, 2025.SEBI Circular dated April 4, 2025, outlines the PaRRVA framework.NSE will serve as the PaRRVA Data Centre (PDC).CARE Ratings will verify risk-return metrics of Investment Advisers, Research Analysts, and Algorithmic Trading Providers.
👀 கவனிக்க வேண்டியவை
Investors should monitor CARE Ratings' performance in this new role and its impact on the company's revenue streams. Keep an eye on any further announcements regarding the implementation of the PaRRVA framework.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
